Source: Eur Respir J, 55 (3) 1900169; 10.1183/13993003.00169-2019
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Claire Bouvard, Nafiisha Genet, Carole Phan, Baptiste Rode, Raphaël Thuillet, Ly Tu, Paul Robillard, Marilyne Campagnac, Raffaella Soleti, Eric Dumas De La Roque, Frédéric Delcambre, Laurent Cronier, Thibaud Parpaite, Elise Maurat, Patrick Berger, Jean-Pierre Savineau, Roger Marthan, Christophe Guignabert, Véronique Freund-Michel, Christelle Guibert. Connexin-43 is a promising target for pulmonary hypertension due to hypoxaemic lung disease. Eur Respir J, 55 (3) 1900169; 10.1183/13993003.00169-2019

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary hypertension in chronic lung disease and hypoxia Source: Eur Respir J, 53 (1) 1801914; 10.1183/13993003.01914-2018 Year: 2019 Treatment of pulmonary hypertension in chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313 Year: 2006 Biomarkers for pulmonary hypertension in interstitial lung disease Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Pulmonary hypertension due to lung disease Source: International Congress 2017 – Russian Programme 2017 Year: 2017 Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease Source: Annual Congress 2012 - Sarcoidosis Year: 2012 Pulmonary hypertension in COPD Source: Eur Respir J 2008; 32: 1371-1385 Year: 2008 The effect of lung diseases on pulmonary hypertension and the effect of pulmonary hypertension on the lung Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Is sildenafil an effective bridging therapy to lung transplantation for patients with pulmonary hypertension in the setting of lung disease? Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Biomarkers in pulmonary hypertension associated to interstitial lung disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Pulmonary hypertension in patients with interstitial lung disease Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant Source: Eur Respir J 2007; 30: 715-721 Year: 2007 A potential role for sildenafil in the management of pulmonary hypertension associated with parenchymal lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Bosentan and pulmonary hypertension in patients affected by chronic obstructive pulmonary disease Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Pulmonary hypertension in patients with COPD Source: Eur Respir Mon 2012; 57: 138-147 Year: 2012 Conclusion: treatment of pulmonary hypertension in COPD patients Source: Annual Congress 2005 - COPD - pulmonary haemodynamics and gas exchange Year: 2005 Pulmonary arterial hypertension and advanced lung disease in cystic fibrosis patients Source: Eur Respir J 2007; 30: Suppl. 51, 387s Year: 2007 Pulmonary arterial hypertension in the patients with chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 512s Year: 2005